Company NovelStem International Corp.

Equities

NSTM

US67001V1098

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Market Closed - OTC Markets Other stock markets 12:07:06 2024-04-24 EDT			5-day change	1st Jan Change
0.06 ^USD	-.--%		-.--%	-4.61%

04-01	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

NovelStem International Corp. is a development-stage biotechnology holding company focused on stem cell-based technology. The Company's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patientsâ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.

Number of employees: 15

Managers	Title	Age	Since
Mitchell Rubenstein FOU	Founder	70	93-01-21
Christine Jenkins DFI	Director of Finance/CFO	61	22-09-28
Jan Loeb CHM	Chairman	64	18-06-30

Members of the board	Title	Age	Since
David Seltzer BRD	Director/Board Member	64	-
Mitchell Rubenstein FOU	Founder	70	93-01-21
Jan Loeb CHM	Chairman	64	18-06-30
Eric Richman BRD	Director/Board Member	63	18-05-31
Tracy Clifford BRD	Director/Board Member	55	18-06-30
Jerry Wolasky BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	50,316,672	16,946,901 ( 33.68 %)	3,435,197 ( 6.827 %)	33.68 %

Name	Equities	%	Valuation
Jerry Wolasky 21.27 %	9,972,973	21.27 %	698 108 $
Jan Loeb 15.83 %	7,420,673	15.83 %	519 447 $
Stephen Gans 15.00 %	7,034,172	15.00 %	492 392 $
David Seltzer 7.091 %	3,324,324	7.091 %	232 703 $
Michael Sosnowik 5.909 %	2,770,270	5.909 %	193 919 $
Tracy Clifford 2.560 %	1,200,000	2.560 %	84 000 $
Mitchell Rubenstein 2.364 %	1,108,108	2.364 %	77 568 $
Eric Richman 1.182 %	554,054	1.182 %	38 784 $
FNY Investment Advisers LLC 0.0533 %	25,000	0.0533 %	1 750 $
Whatifi Asset Management, Inc. 0.006376 %	2,989	0.006376 %	209 $

NovelStem International Corp.

2255 Glades Road Suite 221A

33431, Boca Raton

http://www.novelstem.com

address NovelStem International Corp.(NSTM)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
NOVELSTEM INTERNATIONAL CORP.	-4.61%	2.81M
VERTEX PHARMACEUTICALS INCORPORATED	+5.33%	111B
REGENERON PHARMACEUTICALS, INC.	+12.11%	105B
BIONTECH SE	-12.56%	22.34B
ARGENX SE	-3.70%	21.93B
GENMAB A/S	-6.03%	18.59B
WUXI APPTEC CO., LTD.	-35.21%	18.12B
BEIGENE, LTD.	-10.86%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+5.10%	13.7B
SAREPTA THERAPEUTICS, INC.	+37.57%	12.45B

Bio Therapeutic Drugs